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Effects of combined ACE inhibitor and angiotensin II antago- Proteinuria is a major predictor of decline in renal
nist treatment in human chronic nephropathies. function in patients with non-diabetic, proteinuric renal
Background. Proteinuria predicts renal disease progression, disease. The Modification of Renal Disease (MDRD)and its reduction by angiotensin-converting enzyme inhibitors
[1] and Ramipril Efficacy in Nephropathy (REIN) [2](ACEi) or angiotensin II receptor antagonists (ARA) is reno-
trials found that patients with a greater degree of protein-protective.
Methods. In this prospective, randomized, cross-over study uria had a more rapid decline in glomerular filtration
of 24 patients with nondiabetic, chronic nephropathies, we rate (GFR) and a faster progression to end-stage renal
compared the effects on proteinuria, renal hemodynamics, and
disease (ESRD). The REIN trial demonstrated that anglomerular permselectivity of 8 weeks with comparable blood
initial response to angiotensin-converting enzyme inhibi-pressure control achieved by benazepril (10 mg/day) and val-
sartan (80 mg/day) combined therapy with those achieved by tor (ACEi) therapy, manifested by a decrease in protein-
benazepril (20 mg/day) or valsartan (160 mg/day) alone. uria over the first month of treatment, correlated with
Results. Despite comparable changes in blood pressure and a slowing of the rate of loss of GFR and of progressionglomerular filtration rate (GFR), combined therapy decreased
to ESRD over the following 2 years [2]. The GFR in aproteinuria more than benazepril (56% vs.45.9%, P 0.02)
subset of patients in this trial stabilized and even im-and valsartan (41.5%, P 0.002). Changes in urinary protein
to creatinine ratio followed the same trend. Filtration fraction proved over the 3 years of continued ramipril therapy.
and renal vascular resistances (RVR) decreased more with For each of these patients, the change in GFR slope
combined (14.7%,23.7%) or benazepril (12.4%,20.5%)
while on ACEi was paralleled by a further reduction inthan with valsartan (2.7%,12.5%, P 0.05 vs. both). RVR
24-hour protein excretion [3]. This evidence suggestschanges, adjusted for GFR changes, were associated with those
in proteinuria (P  0.05). Changes in glomerular permeability that decreasing proteinuria, regardless of its cause, is
were comparable and did not predict different changes in pro- beneficial in slowing progressive loss of GFR and in
teinuria in the three groups. reducing the risk of terminal renal failure.Conclusion. At comparable blood pressure, combined ACEi
The best way to reduce proteinuria, however, is unclear.and ARA decreased proteinuria better than ACEi and ARA.
An ACEi has unique antiproteinuric effects not foundThe greater antiproteinuric effect most likely depended on an
ACEi-related hemodynamic effect, in addition to glomerular in other antihypertensive drugs. Blockade of the renin-
size selectivity amelioration. Long-term combined ACEi and angiotensin system (RAS) with ACEi results in a decrease
ARA therapy may be more renoprotective than treatment with
in the glomerular hyperfiltration that follows nephron losseach agent alone.
[4] and in an improvement of glomerular sieving proper-
ties that may be independent of their hemodynamic ef-
fects [5]. ACEi has been shown in multiple animal models
[4] and in long-term clinical studies to reduce proteinuria
and slow GFR decline in diabetic and nondiabetic renalKey words: proteinuria, ACE inhibitors, angiotensin II receptor antag-
onists, glomerular permeability, progressive nephropathies. disease [2, 6]. Angiotensin II receptor antagonists (ARA),
which block the angiotensin II type 1 receptor (AT-R1)Received for publication June 11, 2002
but not the type 2 receptor (AT-R2), appear to be equallyand in revised form August 1, 2002, and September 25, 2002
Accepted for publication October 24, 2002 efficacious as ACEi [7]; however, there are no long-term
studies that directly compare the efficacy of ACEi to 2003 by the International Society of Nephrology
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ARA. The combination of an ARA and ACEi has been accident in the last 6 months, were NYHA class III-IV,
suggested as a way to maximize RAS blockade by affect- had serum potassium of 6 mEq/L, despite control of
ing both the bioavailability of angiotensin II through ACEi metabolic acidosis, clinically significant hepatic disease
and also by affecting its activity at the receptor level. [serum glutamic-oxalacetic transaminase (SGOT), serum
An ACEi has the additional properties of blocking the glutamic-pyruvic transaminase (SGPT), serum alkaline
breakdown of bradykinin, a vasodilator that also stimu- phosphatase 3 times of the upper normal limit, or se-
lates nitric oxide production [4]. ARA do not affect the rum bilirubin 1.5 mg/dL], white blood cell count
activity of the AT-R2, which appears to be important in 3000/mm3, clinical suspicion of renal vein thrombosis,
vasodilation [4]. The combination of these two drugs known hypersensitivity to ACEi or ARA, cancer, collagen
may be a way to block the effects of angiotensin II at the vascular disease, treatment with other investigational
AT-R1 level, while achieving both increased bradykinin drugs, were pregnant or lactating, were not using effec-
levels and activation of the AT-R2. tive contraception, or were unwilling to consent to partic-
Experimental [abstract; Zoja C et al, J Am Soc Nephrol ipation. All patients gave informed consent prior to en-
6:1101, 1995] and human data [8, 9] are available that rolling in the study.
ACEi and ARA in combination more effectively reduce
proteinuria than the two agents alone. However, it is Study protocol
unknown if the combination of these two classes of drugs This was a single-center, prospective, randomized,
is more effective because of a synergistic effect on glo- open-label crossover study comparing the effects of treat-
merular barrier size selectivity or rather because of a ment with either valsartan (A) alone, benazepril (B) or
hemodynamic effect [4, 8–10]. the combination of valsartan and benazepril (C) in three
The primary aim of the study was to test the hypothesis randomized periods of 8 weeks each. The study protocol
that in patients with proteinuric chronic nephropathies, was approved by the Ethics Committee of the Clinical
combined therapy with half doses of ACEi and ARA Research Center for Rare Diseases “Aldo e Cele Dacco`”
may achieve greater reduction of proteinuria than treat- of the Mario Negri Institute of Bergamo.
ment with full doses of each drug alone. Half doses were After obtaining informed consent, the subjects entered
used to achieve comparable blood pressure control in an 8-week run-in period during which any previously
the combined and single agent treatment groups. Second, used ACEi, ARA, and potassium-sparing diuretics were
the study was intended to assess to which extent the stopped. Subjects were allowed to continue loop or thia-
antiproteinuric effect of each treatment was due to an zide diuretics and antihypertensive agents (clonidine) that
effect on glomerular barrier size selectivity or rather on
did not affect glomerular barrier size selectivity to main-
a specific intrarenal hemodynamic effect.
tain a diastolic blood pressure of less than 90 mm Hg.
At the end of the run in period, the patients were ran-
METHODS domized to one of six treatment sequences: ABC, BCA,
CAB, CBA, ACB, or BAC (Fig. 1). Each treatment wasSubjects
given orally at 8:00 a.m. daily for 8 weeks. During eachThe study population was drawn from nondiabetic,
period, the study drug was started at dose level 1 (10 mghypertensive patients with chronic renal disease over the
benazepril, 80 mg valsartan, or 5 mg benazepril and 40age of 18 years attending the Outpatient Clinics of the
mg valsartan) and then increased to dose level 2 after 2Unit of Nephrology of the Ospedali Riuniti of Bergamo
weeks (20 mg benazepril, 160 mg valsartan, or 10 mgor of the Clinical Research Center “Aldo & Cele Dacco`”
benazepril and 80 mg valsartan). Seven days after theof the Mario Negri Institute of Bergamo. Inclusion crite-
start of dose level 2, blood pressure, serum creatinine,ria were a creatinine clearance between 20 and 70 mL/
and potassium were measured. If hyperkalemia or symp-min/1.73 m2 body surface area (BSA) and urinary protein
tomatic hypotension occurred, the dose level was de-excretion rate 1 g/24 hours (average of two measure-
creased to level 1 or the study treatment was withdrawn.ments in two urine collections two weeks apart). Hyper-
The target blood pressure during the study was a dia-tension was defined as sitting diastolic blood pressure
stolic pressure of 90 mm Hg or less. Adjuvant antihyper-between 90 and 115 mm Hg (or less in patients with
tensive (clonidine or loop or thiazide-type diuretics)concomitant antihypertensive therapy). Patients were
agents that do not interfere with the glomerular barrierexcluded if they had a specific contraindication to tempo-
size selectivity were used as needed. Diuretics were heldrarily withdrawal of chronic treatment with ACEi or ARA,
for 24 hours prior to and for 48 hours following the startor received treatment with steroids, nonsteroidal anti-
of a new study drug. Patients were advised not to modifyinflammatory drugs (NSAIDs), immunomodulators, or
their usual protein and sodium intake throughout thecytostatic agents in the last 6 months, had renal vascular
whole study period. At the end of the run-in perioddisease, obstructive uropathy, unstable angina, had suf-
fered an acute myocardial infarction or cerebral vascular (baseline) and at the end of each of the treatment peri-
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Fig. 1. Study design. Patients were random-
ized to six treatment sequences. Each sequence
included four patients. Abbreviations: ACEi,
angiotensin-converting enzyme inhibitor; ARA,
angiotensin receptor antagonist.
ods, three 24-hour collections of urine were obtained for studies after an overnight fast. After induction of diure-
sis, a priming infusion of inulin and PAH was deliveredcreatinine clearance, sodium, and protein measurements.
followed by a sustained infusion. A slow infusion of 130
Measurements mg/kg dextran 40 was given following the loading dose
of inulin and PAH. After an equilibrium period of ap-Prior to the clearance studies, three blood pressure
proximately 40 minutes, three exactly timed urine sam-measurements were taken by automated cuff on the
ples 40 minutes apart were made by spontaneous voidingdominant arm 2 minutes apart with the patient in the
and were collected. Blood samples were collected at thesitting position and after 5 minutes of rest. Systolic and
beginning and end of each clearance period. Urine anddiastolic blood pressures were the average of the three
plasma samples obtained during the first period werereadings. Mean arterial pressure was calculated using the
used to determine the fractional clearance of dextranstandard formula from the average of the three readings.
molecules of graded size (effective molecular radiusBlood chemistries were measured by standard laboratory
ranging from 20 to 70 A˚).techniques from blood samples taken prior to the clear-
ance studies. Twenty-four–hour urine protein measure-
Analytic methodsments were averaged from three 24-hour urine collec-
tions made during the 3 days prior to the clearance Inulin and PAH concentrations in plasma and urine
samples were determined using previously described col-studies. Creatinine clearance and ratio of urinary protein
to urinary creatinine were measured from the last 24- orimetric assays [11, 12]. GFR was calculated as the aver-
hour collection of urine. age of the three inulin clearances. ERPF was calculated
from average PAH clearance assuming a renal extraction
Clearance studies coefficient of 0.7 for patients with a GFR 80 mL/min/
1.73 m2 and of 0.8 for patients with a GFR 80 mL/min/Each patient underwent inulin and para-aminohippuric
acid (PAH) clearance studies to determine GFR and 1.73 m2 [13]. Separation of graded-size dextran molecules
and inulin in plasma and urine samples was performed byeffective renal plasma flow (ERPF), respectively, after
the washout period (referred to as baseline) and at the gel permeation chromatography on a Sephacryl S-300
column (1.65  95 cm) (Amersham Biosciences, Ltd.,end of each treatment period. Filtration fraction (FF)
and renal vascular resistances (RVR) were calculated by Buckinghamshire, UK). Column calibration was per-
formed using dextran standards of known molecular weightstandard formulas.
As previously described [10, 11] the patients were ad- (Pharmacosmos, Viby Sj, Denmark). The molecular ra-
dius of individual dextran fractions was calculated ac-mitted to the metabolic unit the morning of the clearance
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cording to direct measurements of neutral dextran mole- predicted. Assuming, on the basis of previous studies, a
40% reduction with valsartan or benazepril therapy, andcules as previously reported [14] that relate effective
molecular radii and mean molecular weight of neutral considering as clinically relevant a further 20% reduction
with combined therapy, we predicted a decrease in uri-dextran. Urine to plasma concentration ratio for inulin
was calculated from the inulin concentrations in eluted nary proteins from 3.5 to 2.1 g/24 hours with single bena-
zepril or valsartan therapy and from 3.5 to 1.4 g/24 hoursfractions. Fractional clearance of dextran macromole-
cules was computed using: with combined therapy (i.e., from 3.5 to 1.4 g/24 hours).
Thus, with the assumption of a mean standard deviation
	D  (U/P)D / (U/P)IN (SD) difference in urinary protein excretion reduction
between combined and single drug treatments of 0.7 where (U/P)D and (U/P)IN are the urine to plasma concen-
tration ratios of dextran and inulin, respectively. RVR 1.0 g/24 hours, it was estimated that to give the study
an 80% power to detect such difference as statisticallyand FF were calculated using the standard formulas.
significant (P  0.05), 19 patients had to complete the
Theoretical analysis of glomerular membrane transport study.
We investigated intrinsic glomerular membrane per-
Statistical analysismeability properties to macromolecules using the mathe-
matical model of glomerular size selectivity described in The study was a three-period, three-treatment cross-
over study. The possibility that a “period effect” (i.e., adetail previously [12, 15, 16]. This model allows separa-
tion of the effects on membrane permeability changes time-dependent trend that can affect the experiment as
a whole, regardless of the treatment under evaluation)from the effects of glomerular hemodynamic alterations
on glomerular filtration of neutral test macromolecules. or a “carryover” effect (i.e., the persistence of the effect
of a treatment applied in one period in a subsequentThe model assumes that the glomerular membrane is
perforated by cylindrical pores having a bimodal distri- period of treatment) could affect the study findings was
addressed both “a priori” when the study was designedbution of their radii. The radius of restrictive membrane
pores is assumed to have a log-normal probability distri- and “a posteriori,” before performing the final analyses.
To “a priori” prevent or limit the possibility of a “pe-bution. In parallel with selective pores, a shunt pathway
consisting of large pores that do not restrict the passage riod effect,” we introduced a degree of balance into the
study design, with a scheme of randomization allowingof largest macromolecules is also assumed [12, 15]. This
distribution of pore radii is therefore characterized by that every treatment is represented in every period with
the same frequency. Overall, we had six different se-three adjustable parameters: u, s, and
. The parameters
u and s represent the mean and the standard deviation quences with the three treatments valsatran (A), benaze-
pril (B), and their combination (C): ABC, BCA, CAB,of the corresponding normal probabilities distribution,
while 
 represents the fraction of the ultrafiltrate that CBA, ACB, and BAC. An equal number of patients (N
4) per sequence was randomized. Since no patient waswould pass through the shunt if plasma proteins were
absent [12, 15]. The model is based on another freely prematurely withdrawn during the study completion, at
study end this balance was fully respected.adjustable parameter, the ultrafiltration coefficient (Kf),
the product of hydraulic permeability and filtering sur- To prevent or limit the risk of a “carryover” effect, we
planned treatment periods of 8 weeks. Actually, previousface area of the glomerular membrane. We calculated
Kf (extended to the entire glomerular population in both studies (including some from our group) found that the
effects of ACEi and ARA on urinary proteins and glo-kidneys) using an established model of glomerular ultra-
filtration [17]. The intrinsic permeability parameters merular permselectivity are fully reversible within 4 weeks
[7, 11, 12]. Thus, prolonging each treatment period forwere calculated, as shown previously [11, 12], minimizing
the sum of squared errors between experimental and 8 weeks allowed ruling out any residual effect of previous
treatment at week 8, when proteinuria and size selectivitycalculated sieving coefficients, at single patient level, dur-
ing each clearance study. were measured.
To verify that the above design allowed ruling out a
Sample size significant “period” and “carryover” effect, we used the
approach suggested by Senn [18]. Specifically, an “a pos-The sample size was calculated by nQuery Advisor,
release 3.0 (Statistical Solutions, Ltd., Cork, Ireland). The teriori” analysis of variance using SAS General Linear
Models (GLM) procedure (SAS Institute, Inc., Cary,primary efficacy variable of the study was the percent
reduction (versus baseline) in 24-hour urinary protein NC, USA), creating a data set with 72 outcomes (three
each for 24 patients) was carried out. The following vari-excretion rate. On the basis of all patients with chronic,
nondiabetic nephropathies and proteinuria1 g/24 hours ables were created: patients, period, and treat, which
recorded each of the 72 outcomes for which patient itattending our outpatient clinic, a baseline 24-hour uri-
nary protein excretion rate of 3.5  2.0 g/24 hours was was recorded, in which period, and which treatment the
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Table 1. Patient characteristics Clinical and laboratory parameters
Male/female 23/1 Despite comparable changes in systolic and diastolic
Mean age years 48.913.2 arterial blood pressure and creatinine clearance, combinedDiagnosis
treatment with half doses of benazepril and valsartanIgA nephritis 11
Chronic glomerulonephritis (nondiagnostic) 4 decreased 24-hour urinary protein excretion rate (56%
Other 4
vs. baseline) more effectively than full doses of benaze-No biopsy 5
pril (45.9%, P  0.02) or valsartan (41.5%, P 
0.002) alone (Fig. 2). Proteinuria reduction was numeri-
cally superior with benazepril than with valsartan. In 13
patients, maximal proteinuria reduction was achievedpatient was receiving. Patient category was a variable
with combined treatment, in seven patients with benaze-of 24 levels, while period and treat were three each.
pril alone, while in four patients with valsartan alone.Subsequently, it also defined a factor “carry” with levels
Patients with more proteinuria reduction with combinedA, B, or C for the previous treatment and level Z when
therapy had remarkably higher basal proteinuria (4.4 there was no previous treatment. In absence of a statisti-
2.7 g/24 hours vs. 2.1  2.4 g/24 hours and 2.0  1.1 g/24cally significant “period” and “carryover” effect, a
hours, P  0.01 and P  0.05, respectively). In thesematched-pairs t approach was used. Percent changes
patients differences between the levels of proteinuriawere evaluated by means of one-group t test. Relation-
achieved with combined therapy (1.6  1.8 g/24 hours)ships between variables were analyzed by repeated mea-
and those achieved by the other two treatments (benaze-sures of ANOVA mixed models.
pril, 2.4 2.2 g/24 hours; valsartan, 2.8 2.7 g/24 hours)Treatment comparisons of combined therapy versus
averaged about 1 g/24 hours and were both highly sig-valsartan alone and combined therapy versus benazepril
nificant (P  0.001 vs. benazepril and P  0.0001 vs.alone represented the two main contrasts of interest. To
valsartan). In the other two groups, differences betweenadjust for this multiplicity of the two contrasts and to
most effective treatment and the others ranged betweenachieve an overall significance level of P  0.05, each
0.3 and 0.4 g/24 hours. Changes in urinary protein/urinarycontrast was analyzed at a two-sided significance level of
creatinine followed a similar trend with maximal and0.025 (Bonferroni adjustment). No formal comparisons
minimal reductions with combined and valsartan treat-were performed between baseline evaluation and each
ment, respectively, but without significant differencestreatment period and between benazepril and valsartan
between benazepril and valsartan. Serum albumin con-alone.
centration increased with all treatments, the increaseThe skewed distribution of 24-hour urinary protein
being more consistent with combined or benazepril thanexcretion, urinary protein/urinary creatinine ratio (P/C),
with valsartan therapy (Table 2). Total and high-densityalbumin, and neutral dextran fractional clearances were
lipoprotein cholesterol decreased to a similar extent withnormalized by natural logarithmic transformation prior
all treatments (Table 2).to statistical analyses. All evaluations were done with
SAS software (release 8.0). Data were expressed as
Renal hemodynamicsmean  SD, or standard error (SE), as specified in the
The GFR similarly and marginally increased duringtext, or absolute and percent frequencies.
the three treatment periods. The ERPF increased during
all treatment periods, but the increase during combined
RESULTS or benazepril therapy numerically exceeded that observed
Twenty-four subjects were enrolled and all 24 com- during valsartan therapy (Fig. 3). The above changes in
pleted the trial. Twenty-three males and one female were GFR and ERPF resulted in a greater reduction in FF
enrolled in the study. All patients were Caucasian. The during combined or benazepril therapy as compared to
average age of the patients was 48.9 13.2 years. Clinical valsartan therapy alone (Fig. 3 and Table 3). RVR de-
characteristics are listed in Table 1. Twenty-three of the creased during all treatment periods, but the decrease
24 patients achieved the target level 2 dose of each medi- during combined and benazepril was almost double com-
cation. The remaining patient finished the trial while on pared to the decrease observed after valsartan therapy
the level 1 dose. That patient did not advance to the (Fig. 3 and Table 3). As expected, changes in ERPF and
level 2 dose because the diastolic blood pressure was RVR were significantly correlated in the study group as
consistently below 90 mm Hg on the level 1 dose. Before a whole (r  0.737, P  0.0001) and within each treat-
study analyses were performed, no statistically significant ment group (combined: r0.871, P 0.0001; benaze-
“period” (P  0.12) and “carryover” (P  0.86) effect pril: r  0.844, P  0.0001; and valsartan: r  0.689,
P  0.0001).was found.
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Fig. 2. Percent changes from baseline for 24-
hour urinary protein excretion rate, mean ar-
terial pressure (MAP) and creatinine clear-
ance. With Bonferroni adjustment, the level
of statistical significance is P  0.025. Data
are mean  SEM.
Table 2. Clinical characteristics at randomization and at the end of each treatment period
Randomization Valsartan Benazepril Benazepril and valsartan
Systolic blood pressure mm Hg 14013 12912 1269 12412
Diastolic blood pressure mm Hg 918 798 808 789
Mean arterial pressure mm Hg 1078 958 958 9410
24 hour urinary protein g/24 hours 3.282.60 2.042.36 1.761.88 1.391.54a,b
Uprotein/Ucreatinine 1.891.41 1.161.25 1.031.06 0.800.85a,b
Albumin clearance mL/min (103) 489.7805.6 225.4390.4 169.5209.3 156.5248.1b,c
Serum creatinine mg/dL 1.670.46 1.720.42 1.720.43 1.750.46
Creatinine clearance mL/min 69.1419.86 67.8817.21 66.2215.33 67.6518.49
Serum potassium mEq/L 4.10.56 4.330.37 4.450.39 4.630.42b,c
Serum albumin g/dL 3.510.63 3.690.56 3.70.46 3.710.45
Hemoglobin g/dL 14.241.84 13.451.74 13.481.76 13.11.87b,c
Total cholersterol mg/dL 224.2135.09 208.9624.16 207.0828.02 205.8829.02
High-density lipoprotein mg/dL 48.2112.99 40.8813.89 41.6312.51 39.9212.35
Triglycerides mg/dL 177160 202181 181174 163114
24-hour urinary sodium mEq/24 hours 195.4959.21 191.8059.06 200.1257.13 203.5558.76
Data presented as mean  standard deviation, paired t test.
aP  0.01 compared to valsartan
b P  0.05 compared to benazepril
c P  0.05 compared to valsartan
Dextran clearances and theoretical analysis of ning of the study, we assumed a slightly elevated P of
glomerular dextran transport 45 mm Hg at baseline. Because experimental evidence
is available that ACEi and ARA selectively and similarlyThe fractional clearances of neutral dextran molecules
reduce glomerular capillary pressure in animals and sinceof radii ranging from 24 to 70 A˚ are shown in Figure 4.
both normalized blood pressure to a similar extent, weThe sieving profiles at the end of combined and of bena-
assumed that both benazepril and valsartan decreasedzepril or valsartan therapy were comparable.
P to about 40 mm Hg [19, 20]. Since the effect of com-The results of the theoretical analysis of glomerular
bined therapy on arterial blood pressure was similar tohemodynamics and glomerular membrane permeability
that of the two drugs alone, and in the absence of any dataare listed in Table 3. This analysis requires an assumption
in experimental animals, we assumed a P of 40 mm Hgof the transmembrane hydraulic pressure difference (P),
also during combined benazepril and valsartan therapy.as this parameter cannot be measured in humans. Indirect
As a result, the ultrafiltration coefficient Kf listed in Ta-evidence from healthy subjects suggests that P should
ble 3 significantly and similarly increased, and the meanbe close to 40 mm Hg [15]. As our study patients were
hypertensive and without RAS blockade at the begin- pore size u of the corresponding numerical distribution
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Fig. 3. Percent changes from baseline for glo-
merular filtration rate (GFR), effective renal
plasma flow (ERPF), filtration fraction (FF),
and renal vascular resistances (RVR). With
Bonferroni adjustment, the level of statistical
significance is P  0.025.
Table 3. Renal hemodynamic parameters and glomerular membrane permeability characteristics at randomization
and at the end of each treatment period
Randomization Valsartan Benazepril Benazepril and valsartan
Glomerular filtration rate mL/min/1.73 m2 46.512.8 47.914.6 47.713.5 48.117.1
Effective renal plasma flow mL/min/1.73 m2 285102 317127 349125 353129
Filtration fraction % 17.34.9 16.35.1 14.74.6 14.34.2
Kf mL/min/1.73 m2 2.610.91 4.383.41 4.272.48 4.142.34
u A˚ 52.628.51 48.337.13 51.539.16 50.4211.12
s A˚ 1.190.09 1.220.07 1.190.08 1.190.1

o 103 3.222.9 1.351.96 1.241.61 2.023.30
Sum of squared errors 0.970.89 0.930.78 1.121.28 1.411.39
Data presented as mean standard deviation, paired t test
similarly decreased during each of the three treatment clearance occurred throughout the whole study period
periods as compared to baseline. No change occurred in (Table 2). Serum potassium similarly increased during
the standard deviation throughout each treatment pe- each treatment period but the increase did not exceed
riod. The shunt parameter, 
, a quantitative measure 0.5 mEq/L versus baseline and no patient required reduc-
of the importance of the nonselective pore population, tion of drug dose or cessation of therapy because of hyper-
which does not restrict the passage of largest macromole- kalemia. Changes in hemoglobin were not associated
cules, including circulating plasma proteins, similarly de- with symptoms of anemia and did not require therapy.
creased during each treatment period versus baseline
(Table 3).
DISCUSSION
Repeated measures ANOVA mixed models The results from this study demonstrate that 8 weeks
of combined therapy with half doses of benazepril and val-At univariate analysis there was a borderline signifi-
sartan reduced proteinuria more effectively than 8 weekscant relationship between RVR and log-transformed 24-
treatment with full doses of benazepril or valsartan. Thehour urinary protein excretion rate (P 0.087). No rela-
benefit of combined therapy was more consistent, andtionship was found between GFR (P 0.947) or 
 (P
clinically relevant, in patients with more severe, ne-0.694) and 24-hour urinary protein excretion. However,
phrotic-range, proteinuria. In patients with subnephroticwhen the analysis accounted for the borderline interac-
proteinuria, differences between treatments were negli-tion between RVR and GFR (P 0.089), GFR-adjusted
gible and probably reflected random fluctuations moreRVR were significantly associated with 24-hour urinary
than a real superiority of one treatment versus the others.proteins (P  0.046).
The superior antiproteinuric effect was not dependent
Safety on greater blood pressure reduction with combined or
benazepril therapy, as blood pressure control was virtu-The study treatments were well-tolerated by all pa-
tients. No major change in serum creatinine and creatinine ally identical during each treatment period. Nor did the
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Fig. 4. Fractional clearances of neutral dextrans at baseline and at the end of the treatment periods with valsartan, benazepril, and benazepril
and valsartan.
effect depend on further amelioration of the glomerular ther reduced by combined therapy versus ACE inhibi-
tion alone [23]. Thus, whether combined therapy maybarrier size selectivity properties, since combined ther-
apy and the therapy with either of the two drugs alone also increase the antiproteinuric effect of maximized
RAS inhibition achieved by high doses of ACEi or ATAhad virtually identical effects on the shunt pathway and
on pore radii distribution. alone is still matter of investigation.
Measuring size selective function by the fractionalA particular strength of the present study was that for
the first time the potential additional/synergistic effect clearance of graded-size neutral dextran molecules was
instrumental to quantify and compare the effective ame-of combined therapy on urinary proteins was assessed
without the confounding effect of arterial blood pressure. lioration of glomerular barrier permeability achieved by
benazepril, valsartan, or their combination and to assessPrevious studies in diabetic patients with micro- [9] or
macro- [21] albuminuria and nondiabetic patients with to which extent this could account for the different effect
on urinary proteins observed with the three regimens.proteinuria [8] found that more proteinuria reduction
achieved with combined therapy was almost invariably The best fitting of fractional clearance data was obtained
considering the “log-normal shunt” model of glomeru-associated with more blood pressure reduction. Thus,
these studies did not address the central issue of a poten- lar size selectivity. The model showed that the different
treatments, in addition to similarly decreasing the meantial additional or synergistic antiproteinuric effect of com-
bined therapy possibly sustained by a degree of RAS inhi- radius of pores that cross the glomerular barrier, also
had a virtually identical effect on the shunt parameterbition that cannot be achieved by single ACEi or ARA
treatments, even at full recommended doses. Of note, 
, (Table 3). This finding was consistent with a similar
direct effect on glomerular membrane size selective func-the doses of benazepril and valsartan used as single ther-
apy in the present study were equivalent to doses of tion and did not explain the more effective reduction in
urinary proteins achieved by combined benazepril andACEi and ARA previously found to achieve maximal
(and comparable) reduction in proteinuria [7, 22]. On valsartan therapy, as compared to benazepril or valsartan
single therapy.the other hand, a previous study found that when low
doses of losartan (50 mg/day) were added on high doses We did find that, compared to baseline, the ERPF in-
creased with all treatments, the increase being maximalof lisinopril (40 mg/day), urinary proteins were not fur-
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and comparable with combined and benazepril treat- tolerated. There were no significant side effects associ-
ment and quite less consistent (about 50% lower) with ated with the therapy. No patient developed hyperka-
valsartan single treatment. Due to the marginal and com- lemia that mandated withdrawal from the protocol or
parable changes in GFR, this resulted in changes in FF treatment with potassium-binding resins. Serum hemo-
that followed a similar trend (Fig. 3). Finding that the globin levels were significantly lower in the combined
increase in ERPF observed in combined and benazepril treatment period, which was clinically insignificant, and
group strongly correlated with RVR reduction strongly did not require therapy. There was a significant and
suggest that the increased kidney perfusion depended comparable decrease in high-density lipoprotein choles-
on an intrarenal vasodilation largely sustained by the terol during each treatment period that, however, was
inhibition of the converting enzyme. In the study group accompanied by a decrease also in total cholesterol. In
as a whole, reduction in RVR, but not in 
, predicted the present study, the reduction in proteinuria was not
the reduction in proteinuria. This suggests that the better associated with a concomitant decrease in GFR. Of note,
antiproteinuric effect of combined therapy and, albeit to
patients were on an unrestricted water and sodium in-
a less extent, benazepril alone, as compared to valsartan
take, and temporarily withdrew diuretic therapy beforetherapy could, at least in part, depend on a hemodynamic
the first administration of ACEi or ATA. This preventedphenomenon that did not affect glomerular barrier size
the potentiating effect of hypovolemia on acute, hemo-selectivity and plasma protein ultrafiltration. More pro-
dynamically mediated GFR decline observed in patientsteinuria reduction despite comparable glomerular siev-
given low sodium diet or diuretic therapy to enhanceing function may depend on increased tubular protein
the antiproteinuric effects of RAS inhibition [34].reabsorption. A working hypothesis is that in the present
experimental setting, increased protein reabsorption re-
flected an improved tubular function sustained by an
CONCLUSIONimproved perfusion, as documented by increased renal
In conclusion, we found that in chronic nondiabeticblood flow and decreased RVR during combined or
nephropathies the combination of low dose benazeprilACEi therapy. This hypothesis is consistent with experi-
mental evidence that several of the effects of ACEi that and valsartan was safe and well-tolerated. Combined
may contribute to renal protection have been attributed therapy better reduced proteinuria than either agent
to the associated rise in kinins resulting in predominant alone. There was also a trend to greater proteinuria
efferent arteriole dilation and consequent increase in reduction with benazepril than with losartan alone, but
renal blood flow [24–27]. the study was not powered to detect this difference. The
Regardless of the involved mechanisms, the finding different effect on urinary proteins was not dependent
that combined therapy reduced urinary protein excretion on different effects on blood pressure or glomerular bar-
rate more than either benazepril and, more consistently, rier size selectivity, but was most likely related to a hemo-
than valsartan alone has major clinical implications. Reduc- dynamic effect specifically related to the inhibition of
tion in proteinuria is an important goal in the treatment the ACE. These findings call for randomized trials in-
of chronic nephropathy. The importance of decreasing tended to assess whether the antiproteinuric and hemo-
proteinuria was demonstrated by multiple experimental
dynamic effects of combined ACEi and ARA may in
studies showing that early and persistent proteinuria re-
the long-term confer more renoprotection than the twoduction invariably limits or prevents glomerular and tu-
treatments alone, even at comparable blood pressurebulointerstitial damage [28]. Likewise, many prospective,
control. These trials should probably include patientsrandomized trials in diabetic [29, 30] and nondiabetic
with more severe, nephrotic, proteinuria who still have[31] chronic nephropathies invariably found that a de-
a poor prognosis on ACEi or ARA alone, but who alsocrease in proteinuria in response to ACEi or ARA ther-
seem to benefit the most from the superior antiprotein-apy predicted a slowing of the loss of GFR over time
uric effect of combined therapy.and of the progression to ESRD [2]. In animal studies,
proteinuria has been linked to an increase in inflamma-
tory cytokines and mediators such as nuclear factor-B ACKNOWLEDGMENTS
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